Last reviewed · How we verify
Mineralocorticoid Receptor Antagonist
Mineralocorticoid receptor antagonists block aldosterone signaling in the kidneys and other tissues, reducing sodium retention and potassium excretion.
Mineralocorticoid receptor antagonists block aldosterone signaling in the kidneys and other tissues, reducing sodium retention and potassium excretion. Used for Heart failure with reduced ejection fraction, Hypertension, Primary aldosteronism.
At a glance
| Generic name | Mineralocorticoid Receptor Antagonist |
|---|---|
| Also known as | Aldactin, Inspra, spironolactone, eplerenone |
| Sponsor | Cheng-Hsin General Hospital |
| Drug class | Mineralocorticoid receptor antagonist |
| Target | Mineralocorticoid receptor (MR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
These drugs competitively inhibit the mineralocorticoid receptor (MR), preventing aldosterone from binding and activating downstream pathways that promote sodium reabsorption and potassium wasting. By antagonizing MR, they promote sodium and fluid excretion while conserving potassium, leading to reduced blood volume and blood pressure. They are used primarily in heart failure, hypertension, and primary aldosteronism.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Primary aldosteronism
- Post-myocardial infarction
Common side effects
- Hyperkalemia
- Gynecomastia (spironolactone)
- Dizziness
- Headache
- Renal impairment
Key clinical trials
- Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care (NA)
- REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study (NA)
- Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries. (PHASE2)
- Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure (PHASE4)
- Transformative Research in Diabetic Nephropathy 2.0
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Swedish Cardiac And Renal Failure Study-1 (PHASE2)
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |